CD8A and neoplasm: The addition of a MEK inhibitor to vaccination was shown to enhance antitumor response in tumor-bearing mouse models, with increased T cell infiltration, including increased antigen-specific CD8 + T cells, reduced tumor burden, and improved survival [74].